605 Page 1 31-Jul-2026 To Company Name/Scheme ACN/ARSN 1. Details of substantial holder (1) Name ACN/ARSN (if applicable) The holder ceased to be a substantial holder on 29/07/2026 The previous notice was given to the company on 30/07/2026 The previous notice was dated 28/07/2026 2....
Ceasing to be a substantial holder
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Quarterly Activities/Appendix 4C Cash Flow Report
- Becoming a substantial holder
- Data on SAR-bisPSMA to be presented at EANM
- Clarity receives $9.8 million R&D tax incentive refund
- Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma
Later from Clarity Pharmaceuticals
- SECuRE update
- Notification regarding unquoted securities - CU6
- Clarity Pharmaceuticals Announces SECuRE Trial Update on 8 GBq 67Cu-SAR-bisPSMA dose level with two additional complete responses
- Bioshares Biotech Summit Presentation
- Preliminary Final Report
